Updated: Verisk Launches EHR Triage Engine to Help Speed Approval of Life Insurance Applications

Udgivet den 10-08-2020  |  kl. 16:57  |  

Powered by Consumer-Authorized Electronic Health Records, Verisk's Innovative Solution Can Help Streamline Underwriting Decisions

Jersey City, NJ, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Verisk Launches EHR Triage Engine to Help Speed Approval of Life Insurance Applications
Powered by Consumer-Authorized Electronic Health Records, Verisk's Innovative Solution Can Help Streamline Underwriting Decisions

JERSEY CITY, N.J., August 10, 2020 -- Verisk (Nasdaq:VRSK), a leading data analytics provider, announced today the launch of its new EHR Triage Engine, a tool that uses data from consumer-authorized electronic health records (EHRs) to help life insurers fast-track many applications for coverage--potentially cutting decision time from weeks to minutes.

The EHR Triage Engine bypasses manual workflows, leveraging advanced predictive analytics and automation to digitally ingest and analyze EHRs. The tool can evaluate 95,000 impairments in five minutes or less, so life insurers can qualify as much as 85 percent of applicants for coverage with minimal or no underwriter review. With automated processing of low-risk cases, carriers can provide a streamlined customer experience for the vast majority of their applications and enable underwriters to focus their energy on complex risks.

"Many life insurers are looking to implement digital strategies to modernize and streamline their business for a competitive advantage," said Maroun Mourad, president of global underwriting at Verisk. "Verisk is at the forefront of a revolution in analyzing structured digital health data for insurers that's shared by their applicants, and is indispensable for automating real-time, low-, or no-touch decision making. This can help insurers deliver a quick purchase process for the vast majority of applicants who are relatively low risk."

Research shows that it takes four weeks to underwrite the average life policy, but half of all life insurance shoppers are more likely to buy if they can forego the most intrusive and time-consuming element--a required physical exam. The EHR Triage Engine helps respond to those customer expectations, an effort supported by a team of Verisk experts in biostatistics, data science, medical research, regulatory compliance, and data privacy.

Verisk developed the EHR Triage Engine in collaboration with SCOR, a global Tier 1 reinsurer. SCOR plans to integrate Verisk's EHR Triage Engine into SCOR Global Life's Velogica underwriting system. The Verisk solution can also be easily delivered via a stand-alone API or integrated into technology from FAST, a Verisk business and leading provider of end-to-end software for the life insurance and annuity markets.

For more information, visit: For more information, visit the EHR Triage Web page.

About Verisk 
Verisk (Nasdaq:VRSK) is a leading data analytics provider serving customers in insurance, energy and specialized markets, and financial services. Using advanced technologies to collect and analyze billions of records, Verisk draws on unique data assets and deep domain expertise to provide first-to-market innovations that are integrated into customer workflows. Verisk offers predictive analytics and decision support solutions to customers in rating, underwriting, claims, catastrophe and weather risk, global risk analytics, natural resources intelligence, economic forecasting, and many other fields. Around the world, Verisk helps customers protect people, property, and financial assets.

Headquartered in Jersey City, N.J., Verisk operates in 30 countries and is a member of Standard & Poor's S&P 500® Index and part of the Nasdaq 100 Index. For more information, please visit www.verisk.com.

About SCOR, a Global Tier 1 Reinsurer

SCOR, the world's fourth largest reinsurer, offers its clients a diversified and innovative range of solutions and services to control and manage risk. Applying the "The Art & Science of Risk", SCOR uses its industry-recognized expertise and cutting-edge financial solutions to serve its clients and contribute to the welfare and resilience of society.

SCOR offers its clients an optimal level of security with its AA- rating from S&P and Fitch. The Group generated premiums of more than EUR 16 billion in 2019, and serves clients in more than 160 countries from its 38 offices worldwide.

For more information, visit: www.scor.com

Contact:

Joe Madden for Verisk
Joseph.Madden@verisk.com
201-232-4486

Brett Garrison
Edelman (for Verisk)
Brett.Garrison@edelman.com
917-639-4903

\Hugin

Udgivet af: NPinvestordk

Seneste nyheder

17:18 Novo banket i bund efter skuffende data - aktionærerne tabte omkring 690 mia. kr.
17:06 Fredagens aktier: Øretæver til Novo Nordisk og Zealand Pharma giver solid C25-nedtur
15:46 USA/åbning: Eli Lilly vinder på Novos kollaps mens inflationsdata skærer lidt af dykket
15:17 Jeudan har milliarder klar til opkøb: "Øget optimisme kan give flere transaktioner i 2025"
15:15 Novo/Jyske Bank: Kursreaktion virker som overreaktion
14:29 USA/tendens: Eli Lilly vinder på Novos kollaps mens frygt for nedlukning varsler rød start
13:33 Korr: Udsalg af Novo-aktier presser kronen
13:24 Udsalg af Novo-aktier presser kronen
12:29 Sydbank-analytiker: Voldsomt kursfald afspejler skuffelsen over Cagrisema-data
12:25 Europa/aktier: Danske fedmeaktier bløder og trækker Europa i rødt
12:22 Novo smadres på børsen efter skuffende fedmestudie - aktien taber 770 mia. kr.
12:11 Novos styrtdyk trækker C25-indekset ned i sit fjerdestørste fald nogensinde
12:09 Gubra og Zealand Pharma trækkes med ned af negativt nyt til Novo Nordisk
12:05 Novo lever ikke op til egne forventninger i vigtigt studie - aktien mister 900 mia kr -NY2
11:56 Novo lever ikke op til egne forventninger i kursfølsomt studie - aktien mister 700 mia kr
11:48 Aktier/middag: Zealand Pharma bankes tocifret ned efter FDA-afvisning og trækker C25 ned
11:28 Obligationer/middag: Små renteudsving før inflationsnyt fra USA
10:49 Jefferies ser kurslussing til Zealand Pharma som købsmulighed
10:19 FLSmidth foreslår Mads Nipper som ny bestyrelsesformand
09:18 Zealand Pharma bankes i bund på børsen efter FDA-afvisning - aktionærer taber 5,3 mia. kr.